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Variation in response to biologic therapy for inflammatory diseases, such as psoriasis, is partly driven by variation in drug 
exposure. Real-world psoriasis data were used to develop a pharmacokinetic/pharmacodynamic (PK/PD) model for the first-
line therapeutic antibody ustekinumab. The impact of differing dosing strategies on response was explored. Data were col-
lected from a UK prospective multicenter observational cohort (491 patients on ustekinumab monotherapy, drug levels, and 
anti-drug antibody measurements on 797 serum samples, 1,590 measurements of Psoriasis Area Severity Index (PASI)). 
Ustekinumab PKs were described with a linear one-compartment model. A maximum effect (Emax) model inhibited progres-
sion of psoriatic skin lesions in the turnover PD mechanism describing PASI evolution while on treatment. A mixture model 
on half-maximal effective concentration identified a potential nonresponder group, with simulations suggesting that, in 
future, the model could be incorporated into a Bayesian therapeutic drug monitoring “dashboard” to individualize dosing and 
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Study Highlights
WHAT IS THE CURRENT KNOWLEDGE ON THE 
TOPIC?
✔  There is significant variation in response to biologic 
therapy in immune-mediated diseases, some of which is 
driven by differences in drug exposure. Ustekinumab is a 
monoclonal antibody targeting the p40 subunit common 
to IL-12/23, and is widely used in the treatment of psoria-
sis and inflammatory bowel disease. Studies investigating 
therapeutic drug monitoring and dose individualization for 
ustekinumab are limited.
WHAT QUESTION DID THIS STUDY ADDRESS?
✔  Can pharmacokinetic/pharmacodynamic (PK/PD) mod-
eling define dose adjustments that will improve outcomes 
in patients with psoriasis treated with ustekinumab?
WHAT DOES THIS STUDY ADD TO OUR KNOWLEDGE?
✔  Our PK/PD model reinforces findings from phase III 
clinical trials, and we additionally characterize a mixed 
distribution of half-maximal effective concentration that 
could identify responder and nonresponder subgroups. 
Model simulations suggest that dose escalation/interval 
reduction may benefit partial responders.
HOW MIGHT THIS CHANGE CLINICAL PHARMA-
COLOGY OR TRANSLATIONAL SCIENCE?
✔  Incorporating these findings into a Bayesian thera-
peutic monitoring algorithm could facilitate individualized 
ustekinumab dosing, including identifying nonresponders 
for early switching. These findings may be generalizable 
to other disease settings.
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The advent of biologic therapies means that complete 
disease remission is now achievable in patients with 
immune-mediated inflammatory diseases, including psori-
asis, rheumatoid arthritis, and inflammatory bowel disease. 
Nevertheless, poor response or loss of response remains 
a significant problem for many,1–3 and is at least partly ex-
plained by differences in drug exposure. This, in turn, is 
influenced by treatment adherence and pharmacokinetic 
(PK) factors, including bodyweight and the development 
of anti-drug antibodies (ADA). Interest has, therefore, cen-
tered on therapeutic drug monitoring (TDM) to guide dosing 
for individual patients in an adaptive and timely fashion, and 
potentially to reduce clinical costs.4–6
Broadly speaking, TDM strategies advocate population- 
based target trough concentrations for dose adjustment, 
using a reactive rather than proactive approach.7–9 Integration 
of pharmacodynamic (PD) outcomes to yield PK/PD 
models is rare, but these could feasibly be included in 
Bayesian prediction algorithms to predict and adjust dosing 
strategy on an individual level.10,11 To date, investigation of 
the effectiveness and utility of TDM has largely been con-
fined to tumor necrosis factor inhibitors, the first of many 
cytokine-targeted biologic therapies in immune- mediated 
inflammatory diseases.
Ustekinumab, a highly effective biologic targeting the 
IL23-Th17 canonical pathway, is a fully human immuno-
globulin G1 kappa monoclonal antibody binding to the 
p40 subunit shared by IL-12 and IL-23. Initially developed 
for psoriasis12 (where it remains first-line), it is now also li-
censed for use in psoriatic arthritis and inflammatory bowel 
disease.13,14 Studies investigating the relationship between 
ustekinumab exposure and outcome are few, generally lim-
ited to descriptive or empirical analyses, and report mixed 
results.15–19 Understanding exposure-response is com-
plicated by the fact that some patients’ disease may not 
respond to IL-23-Th17 therapies, and furthermore, some 
may receive subtherapeutic drug exposure due to PK 
variability.
Ustekinumab dosing for psoriasis comprises a fixed dose 
(45  mg/90  mg) stratified by bodyweight (less/more than 
100 kg, respectively) given subcutaneously at week 0, week 
4, and then 12-weekly. Real-world data show that those with 
higher baseline body mass index are less likely to respond,20 
and more likely to need higher cumulative doses over the 
first year of treatment,21 suggesting that a proportion of 
patients may have insufficient drug exposure. On the other 
hand, a recent phase IIIb study reports a subset of patients 
in who complete response was maintained, despite length-
ening the dosing interval.22
Psoriasis represents an ideal disease model to investi-
gate the utility of TDM,6,23 because treatment response is 
visually observed and easily quantifiable over time. Here, we 
use a large-scale real-world data  set from the multicenter 
cohort study Biomarkers of Systemic Treatment Outcomes 
in Psoriasis (BSTOP), within the UK pharmacovigilance 
registry British Association of Dermatologists Biologics 
and Immunomodulators Registry (BADBIR). This resource 
captures deep clinical phenotyping, including serum usteki-
numab sampling and ADA measurements, along with 
repeated, longitudinal measures of clinical severity using the 
validated tool known as the Psoriasis Area and Severity Index 
(PASI).24 The PASI score ranges from 0-72, and the usual 
biologic treatment eligibility threshold is ≥ 10. Response is 
judged as the percentage reduction in PASI from baseline 
(e.g., “PASI75” means a 75% decrease in PASI).
As a first step to exploring the clinical potential of a 
Bayesian therapeutic monitoring algorithm for ustekinumab, 
we applied PK/PD modelling to this real-world data set to 
investigate the relationship between ustekinumab expo-
sure and treatment response, and compared our findings to 
published PK and PD models derived from phase III clinical 
trials.25,26 We also simulated the impact of alternative dos-
ing regimens on response, and explored the clinical utility of 
early assessment of trough concentration and PASI change 
from baseline.
MATERIALS AND METHODS
Patient and data
Ethics approval. This study was conducted in the spirit 
of the 1996 International Conference on Harmonisation in 
Good Clinical Practice (ICH-GCP) 1996, and in accordance 
with the 2008 Declaration of Helsinki. Two studies provided 
samples and data within the Psoriasis Stratification to 
Optimise Relevant Therapy (PSORT) consortium, aiming 
to understand determinants of response to biologics: 
BSTOP (approved by The South East London REC 2 Ethics 
Committee, 11/H0802/7), and its nested study PSORTD 
(PSORT Discovery; approved by the National Research 
Ethics Service Committee London – London Bridge, 14/
LO/1685). Written informed consent was obtained from all 
subjects prior to enrollment.
Patients and setting
BSTOP is a prospective multicenter (n = 60) observational 
study, established in 2011 following a 2009 pilot, aiming to 
identify markers of outcomes to systemic therapies in pso-
riasis. All UK adults fulfilling BSTOP inclusion criteria27 and 
enrolled onto BADBIR28 were invited to participate. BADBIR 
has recruited >  18,000 patients since 2007, and includes 
patients with: dermatologist-diagnosed psoriasis; age 
>  16  years; and started on, or switched to a conventional 
systemic therapy or a biologic therapy within the previous 
6 months. Detailed information is recorded, including demo-
graphics, comorbidities, treatments, and adverse effects. 
Clinical response is assessed longitudinally using the gold 
standard assessment tool PASI.24 PSORTD is a nested 
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study with the same inclusion criteria, embedded within the 
BSTOP clinical site network (11/79 centers), collecting sam-
ples at rigorously defined time points within the first 3 months 
of treatment. For the current study, inclusion criteria were: 
patients enrolled onto BSTOP and/or PSORTD, taking usteki-
numab monotherapy, and with ≥ 1 serum sample and ≥ 1 
recorded PASI within a year after starting treatment.
Drug level and ADA measurements
Venous blood samples were collected between June 2009 
and December 2016 during routine clinic visits. All sam-
ples were centrifuged at 2,000 g for 10 minutes and serum 
aliquots frozen (−80°C). In this pragmatic study, samples 
were not collected from every patient at every time point, 
and most were taken without reference to treatment ad-
ministration (i.e., trough/non-trough not specified). The 
ustekinumab assay was an enzyme-linked immunosorbent 
assay29 using IL-12 as a target to capture ustekinumab 
with a lower limit of detection 0.02 µg/mL. ADA were mea-
sured using a radioimmunoassay30 with a positive cutoff 
at 12 arbitrary units/mL. If several ADA measurements 
were available for the same patient, only the measurement 
with the highest titer was included for analysis.
Clinical outcome measures
Psoriasis severity was measured using PASI.24 PASI score 
at 6  months was used to categorize patients into  three 
responder types: full responders achieving ≥  75% PASI 
decrease from baseline (PASI75); partial-responders 
≥  50% and <  75%  decrease from baseline (PASI50-
75); and nonresponders <  50%  decrease from baseline 
(PASI < 50).
Ustekinumab real-world PKs/PDs
A sequential population PK then PD model was developed 
using nonlinear mixed-effects modeling in NONMEM (ver-
sion 7.3).31 The PK model included all patients, whereas the 
PD model was developed on the subset of patients with 
baseline PASI ≥ 10, because current treatment guidelines 
restrict biologic therapy to patients with a PASI ≥ 10.
The PK structural model was one-compartment with 
first-order subcutaneous absorption and first-order elimina-
tion (see Supplementary Materials for the final structural 
model and NONMEM code). Allometric scaling weight scal-
ing centered on 70 kg was added a priori with an exponent 
of 0.75 on clearance and 1 on volume.32
A turnover model was used to describe PASI evolution over 
time (see Supplementary Materials for the final structural 
model and NONMEM code). Drug effect was via a maximum 
effect (Emax) model inhibiting the Kin parameter (i.e., devel-
opment/progression of psoriasis skin lesions). Upon finding 
a possible bimodal distribution on half- maximal effective 
concentration (EC50), a mixture model using the NONMEM 
$MIXTURE regime was used.33
Covariate selection and model evaluation
Baseline demographics (age, sex, and ethnicity), alco-
hol and smoking status, anthropometric measures (body 
mass index and waist circumference), psoriasis character-
istics (disease duration, involvement of palms/soles, and 
psoriatic arthritis), and comorbidities were tested using the 
Stepwise Covariate Model-building method34 with forward 
selection (P = 0.05) and backward elimination (P = 0.01) 
based on the likelihood ratio test.35 Only covariates re-
corded in ≥  10% of patients were tested. For missing 
covariates, the missing values of continuous covariates 
were replaced with the medians, and the missing values of 
categorical covariates were replaced with the most com-
mon numerical categories of individual covariates.34
Model fit was assessed using plots of observations vs. 
model predictions, standardized residuals, likelihood-based 
diagnostics (via the NONMEM objective function value), and 
assessment of model simulation properties via the visual pre-
dictive check (VPC).36 Plots were created using R (R Core 
Team. R: A language and environment for statistical computing. 
Vienna, Austria: R Foundation for Statistical Computing; 2019).
Simulation of dose adjustment
Guidelines suggest that ustekinumab is stopped if PASI75 
has not been achieved by 16 weeks.12 We therefore explored 
whether switching to alternative dosing regimens, after the 
initial 16 weeks of standard treatment, may impact the prob-
ability of achieving PASI75/PASI90 (clear/almost clear on the 
Physician’s Global Assessment). Specifically, we simulated 
1,000 patients (63% full-responders, 23% partial-responders, 
and 14% nonresponders; i.e., the same proportions as ob-
served in the cohort) for two dosing groups 45 mg and 90 mg, 
taking into account individual variability and significant PK 
covariates. Beyond 16  weeks, we simulated two  potential 
alternative dosing frequencies (i.e., 8-weekly and 16-weekly, 
alongside the standard 12-weekly regimen). To assess 
change in dosing level, we also performed simulations using 
covariates from the patient group receiving 45 mg, but with an 
administered dose of 90 mg.
Identifying a target trough concentration for response 
at 6 months
To determine an early target trough concentration predictive 
of an 80% probability of longer-term response (as defined 
by PASI75 at 6  months), 1,000 patients were simulated 
based on parameter estimates in the mixture 1 subpopu-
lation. This was performed separately for both 45 mg and 
90 mg doses on the standard regimen. Individual variabil-
ity and significant PK covariates were taken into account 
during simulation. The trough concentrations at week 4 
(median and 95% prediction interval) were then derived for 
an 80% probability of PASI75 at 6 months.
Individual predictions of ustekinumab trough concen-
tration at week 4 were plotted against the observed PASI 
change from baseline by 4 weeks for all patients to deter-
mine whether early response and trough concentration were 
related to 6-month outcome.
RESULTS
Patients and data
Within a prospective multicenter observational study (60 
dermatology centers across the United Kingdom), we 
identified 491 patients with psoriasis on ustekinumab 
monotherapy fulfilling our inclusion criteria. Ustekinumab 
drug levels and ADA measurements were derived from 
403
www.cts-journal.com
Real-World PK/PD Study of Ustekinumab in Psoriasis
Pan et al.
797 serum samples, and 1,590 PASI measurements 
were available over the first year of treatment. The per-
centages of subjects with 1/2/3/4/5 serum samples were 
58.9/22.8/15.9/2.0/0.4, respectively. Of 491 patients, 
there were 239 responders, 107 partial-responders, 131 
nonresponders, and 14 with unknown response. Of note, 
the average number of serum samples per patient was 
similar between responders and nonresponders (1.7 vs. 
1.6, respectively).
The PK model included all patients’ PASI measurements, 
whereas the PD model included 348 patients and 1,136 
PASI measurements. PD results from all 491 patients can be 
found in Table S1 (Supplementary Materials).
Baseline characteristics of the cohort (Table 1) were con-
sistent with the psoriasis population prescribed biologic 
therapy: mostly  men (65.2%), with severe longstanding 
disease (median PASI 12.1; median disease duration 
21.0 years), and a comorbidity profile dominated by features 
of the metabolic syndrome (median weight 91.8 kg, diabe-
tes mellitus 12.6%, and hypertension 28.7%). There were 
40.9% of patients who were biologic-naïve, and 57.4% were 
on 45  mg ustekinumab vs. 42.6% on 90  mg. No patients 
were recorded to have changed dose or dosing interval 
during the first year of treatment.
Ustekinumab real-world PK
As expected, ustekinumab PKs were linear,37 and ad-
equately described using a one-compartment model. 
Parameter estimates are summarized in Table 2. The ab-
sorption rate constant, apparent clearance, and volume of 
distribution (0.23 day−1, 0.44 L/day, and 10.2 L) were similar 
to those reported in ustekinumab phase III development 
(0.35 day−1, 0.47 L/day, and 15.7 L).25
Between-subject variability (BSV) was 44.7% and 
36.5% for clearance and volume of distribution, respec-
tively. Relative SE values ranged from 6.7% to 42.7%. A 
VPC (Figure 1, left panel) indicated that the PK model ad-
equately described the serum ustekinumab concentration 
over time.
In addition to a priori allometric weight scaling, waist cir-
cumference and alcohol consumption were associated with 
increased apparent clearance (P < 0.01), whereas increased 
creatinine and biologic-naïve status had the opposite effect 
(P < 0.01). Of note, when waist circumference was excluded 
from the model, diabetes status became a significant co-
variate (data not shown; diabetes status not included in 
the final model). In patients with measurable ADA (n = 16), 
clearance was higher than in those with nonmeasurable ADA 
(P > 0.05) and increased with increasing ADA level (Figure S2 
in Supplementary Materials).
Mixture modeling separates full-responders and 
nonresponders in the PD model
Table 3 summarizes the PD model parameter estimates. 
The estimated EC50 (concentration of ustekinumab giving 
50% of the maximum IL-12/IL-23 inhibition) was 0.14 μg/mL, 
with large BSV (148.3%), which was not associated with any 
of the covariates using either manual or automatic selection 
methods. The BSV had an asymmetric bimodal distribution 
(Figure 2), and inclusion of a bimodal distribution on EC50 
using $MIXTURE significantly improved model fit. The two 
subpopulations comprised 76.2% and 23.8% of patients, 
Table 1 Summary of baseline variables for all patients (n = 491), including demographics, disease characteristics, and comorbidity burden
Variable Median or percentage Range Missing (%)
No. of serum measures per subject 1.6 (1–5) –
No. of PASI measures per subject 3.2 (1–8) –
No. of ustekinumab doses per subject 6 (1–6) –
Duration of therapy per subject (year) 1 (0–1) –
Sex (male, %) 65.2 – 0.0
Age (year) 45.5 (18.9–81.2) 0.0
Ethnicity (white, %) 85.7 – 0.0
Weight (kg) 91.8 (48.2–174) 11.4
BMI (kg/m2) 30.5 (18.0–60.2) 13.0
Waist (cm) 104 (65–161) 14.5
Alcohol (yes, %) 63.3 – 3.9
Smoking (yes, %) 25.1 – 3.9
Baseline PASI 12.1 (0–39.7) 24.2
Disease duration (year) 21.0 (1.0–68) 8.8
Palms/sole involvement (yes, %) 18.9 – 10.2
Inflammatory arthritis (yes, %) 22.2 – 7.3
Biologic-naïvea (yes, %) 40.9 – 0.0
Comorbidity (yes, %) (AS/MDD/DM/DLP/HT/LD) 11.2/17.3/12.6/10.0/28.7/10.0 – 3.7/3.7/3.7/3.7/3.7/3.7
Creatinine (μmol/L) 78 (46–403) 36.3
Median or percentage: median values for continuous variables or percentage for categorical variables, missing (%): the percentage of records for a variable 
not available.
AS, asthma; BMI, body mass index; DLP, dyslipidemia; DM, diabetes mellitus; HT, hypertension; LD, liver disease; MDD, major depressive disorder; PASI, 
Psoriasis Area and Severity Index.
aFive of 491 (1.0%) patients had received ustekinumab prior to the study period.
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respectively. Mixture group 1 had a typical EC50 of 0.07 μg/mL, 
whereas in mixture group 2 the EC50 was 1.21  μg/mL 
(Table 3). A VPC plot (Figure 1, right panel) indicated that 
the PK/PD model adequately described the PASI change 
from baseline over time.
Comparing the mixture model classification with the ac-
tual observed response rate at 6 months, mixture group 1 
comprised 68.6% who achieved PASI75 (full-responders), 
24.0% who achieved PASI50-75 (partial-responders), and 
7.4% who achieved PASI < 50 (nonresponders). By contrast, 
mixture group 2 comprised only 5.4% full-responders, 
23.2% partial-responders, and 71.4% nonresponders. 
Most full-responders, therefore, appeared in mixture group 
1 (low EC50), whereas most nonresponders appeared in 
mixture group 2 (high EC50). There was an even proportion 
of partial responders in each group, but further $MIXTURE 
stratification into three subpopulations did not improve 
model fit.
Simulations to explore alternative ustekinumab dose 
regimens
We used the final parameter estimates from the mixture model 
(with EC50 values consistent with being in mixture groups 1 
and 2, respectively), to explore the impact of alternative dos-
ing regimens on response outcomes (Figure 3). Simulated 
profiles for the standard dose and interval (12-weekly) showed 
a sustained response over time, and a higher probability of 
achieving PASI75 for patients on 90 mg compared with 45 mg 
overall. For  patients in mixture group 1, the probability of 
achieving PASI75 after 1 year of treatment could be increased 
toward 100% by reducing the dosing interval from 12-weekly 
to 8-weekly. For patients in mixture group 2, the probability 
of achieving PASI75 could only be substantially increased in 
patients on 45 mg, and only to around 20%. None of these 
simulated interventions seemed to impact on the probability 
of achieving PASI90 (Figure S3, right-hand panel).
To explore whether increasing the dosing interval may be 
possible in patients with good response, simulation using 
a typical EC50 from mixture group 1 subpopulation (mainly 
full-responders) suggested that the probability of achieving 
PASI75 dropped from near 75% to below 50% when the 
dosing interval changed from 12-weekly to 16-weekly, with a 
substantial decrease also seen in the 90 mg group (Figure 3, 
Table 2 Parameter estimates from the ustekinumab PK model for all 
patients (n = 491)
Parameter (unit) Estimate RSE (%)
ka (/day) 0.23 16.1
CL/F (L/day) 0.44 6.7
V/F (L) 10.2 8.2
BSV on CL (%) 44.7 10.3
BSV on V (%) 36.5 28.9
corr CL and V 0.37 21.1
coeffweight on CL 0.75 (fix) –
coeffweight on V 1 (fix) –
coeffbionaïve on CL −0.13 34.1
coeffcreatinine on CL −0.36 35.5
coeffwaist on CL 0.84 18.0
coeffalcohol on CL 0.15 42.7
Proportional error (%) 61.3 3.2
Additive error (SD) 0.007 13.7
BSV, between-subject variability; CL/F, apparent clearance; coeff, coef-
ficient of a covariate on CL or V; corr, correlation coefficient between CL 
and V; ka, absorption rate constant of ustekinumab; PK, pharmacokinetic; 
RSE, relative standard error; SD, standard deviation; V/F, apparent volume.
Figure 1 Visual predictive check for ustekinumab pharmacokinetic model (left), and pharmacodynamic mixture model (right). The 
95% prediction intervals are shown for predicted data in grey (97.5th and 2.5th percentiles top and bottom, respectively) and blue 
(50th percentile) bands with corresponding observed percentiles shown as broken black (97.5th and 2.5th percentiles top and bottom, 
respectively) and solid black (50th percentile) lines. PASI, Psoriasis Area Severity Index; USK, ustekinumab.
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left-hand panel). A similar pattern was seen for the prob-
ability of achieving PASI90 (Figure S3 in Supplementary 
Materials, left-hand panel).
To explore whether increasing the ustekinumab dose may 
improve response, we also simulated a 90 mg dose using pa-
rameters from the patient group on 45 mg (Figure 3, bottom 
panel). This suggested that in patients on 45 mg, increasing the 
dose to 90 mg is less likely to improve response than reducing 
the dosing interval from 12-weekly to 8-weekly.
Toward early stratification of subsequent response: 
Early trough concentration and initial PASI reduction 
from baseline
The licensed first dose interval of ustekinumab is 4 weeks to 
create a loading dose effect; therefore, week 4, immediately 
prior to the second dose, represents a possible early in-
tervention point. A target of 1.4  mg/L (expected variability 
0.4–3.4  μg/mL) was identified as the median 4-week drug 
concentration if the dose was adjusted to project an 80% 
response rate at 6 months for the mixture 1 subpopulation 
(Figure 4). Based on this qualitative interpretation of Figure 4, 
we next performed exploratory analysis using individual pre-
dictions of ustekinumab concentrations and PASI response.
In the subset of observed patients with PASI ≥  10, in-
dividualized predictions of 4-week ustekinumab trough 
concentration and 4-week change from baseline PASI were 
evaluated with respect to three 6-month responder catego-
ries: full (PASI75), partial (PASI50-75), and nonresponder (PASI 
< 50). Responders tended to have higher trough concentra-
tions and large initial PASI reduction from baseline, whereas 
nonresponders demonstrated low trough concentration and 
small initial PASI reduction (Figure 4a,b). We therefore di-
vided simulated patients into four groups based on a trough 
concentration cutoff of 1.4 μg/mL (as above), with a pragmat-
ically selected 4-week PASI25 (Figure 4c). The subsequent 
6-month response profiles for each group imply that 4-week 
trough concentration could be combined with initial PASI tra-
jectory to begin to stratify probable responder phenotype.
DISCUSSION
Key findings
Using psoriasis as a disease model, we present the first 
real-world study investigating the PK/PD relationship be-
tween serum ustekinumab levels and treatment response. 
PK/PD findings from our study support those reported 
from clinical trials, although we were able to identify 
two responder subpopulations in our PD mixture model, 
whereas this was not reported in the trial data. Our mix-
ture model suggests that there are two subpopulations of 
low and high EC50 values, which largely separate patients 
achieving 6-month PASI75 (full-responders) and patients 
failing to achieve PASI50 (nonresponders). Within the high 
EC50 group, there are likely to be a subgroup of true non-
responders for whom no amount of ustekinumab will be 
effective. However, our exploratory simulations suggest 
that dose escalation may improve probability of response 
toward 100% in patients already achieving at least 
PASI50-75 (partial-responders), whereas this approach 
does not seem to substantially improve probability of 
response in nonresponders (Figure 3). At 4 weeks, com-
bined trough ustekinumab concentration and change in 
PASI could be used as a guide to determine likely clinical 
outcome at 6 months (Figure 4).
The PK/PD model
Our ustekinumab PK findings are largely consistent 
with those estimated from clinical trial data, includ-
ing absorption rate constant, clearance, and volume of 
distribution.25 A broadly similar approach to covariate 
selection was adopted to that taken by Zhu et al.25, but 
also included factors known to influence response to bi-
ologics across the BADBIR cohort.38 Covariates that we 
found to be significantly associated with clearance over-
lapped with those from the published model.25 Of note, 
Zhu et al.25 reported a positive relationship between 
Table 3 Parameter estimates for patients with baseline PASI ≥ 10 
(n = 348) using two different ustekinumab PD models
Parameter (unit)
Estimate from 
single model 
(RSE%)
Estimate from 
mixture model 
(RSE%)
Baseline PASI 15.5 (4.4) 15.8 (4.2)
kout (/day) 0.02 (6.9) 0.02 (7.3)
Emax 1 (fix) 1 (fix)
EC50 (μg/mL) 0.14 (15.0) Mixture 1: 0.07 (17.3)
    Mixture 2: 1.21 (22.2)
BSV on baseline (%) 43.6 (7.3) 41.4 (7.6)
BSV on kout (%) 66.4 (7.9) 66.9 (8.8)
BSV on EC50 (%) 148.3 (9.5) 42.7 (58.2)
Additive error (SD) 3.3 (1.7) 3.3 (1.7)
delta OBJV – −12.2
Single model: patients treated as from a single population, mixture model: 
automatic stratification into two subpopulations using $MIXTURE.
BSV, between-subject variability; , delta OBJV, objective function value 
change from single model; EC50, concentration at 50% of maximum inhi-
bition on IL 12 and 23; Emax, maximum inhibition effect of ustekinumab; 
kout, elimination rate constant of skin lesions; PASI, Psoriasis Area Severity 
Index; PD, pharmacodynamics; RSE, relative standard error; SD, standard 
deviation. 
Full-responders: ≥ 75% reduction from baseline; partial-responders: ≥ 50% 
and < 75% reduction from baseline; nonresponders: < 50% reduction from 
baseline.
Figure 2 Distribution of random effects (ETA) of EC50 in 
the single population model. Solid blue line: density of the 
distribution. EC50, concentration of ustekinumab giving 50% of 
the maximum IL-12/IL-23 inhibition.
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creatinine clearance and drug clearance, and in line with 
this we found increased serum creatinine concentration 
to be associated with reduced drug clearance (creatinine 
clearance values were not derived in our study). Because 
ustekinumab is not primarily cleared via the kidneys, this 
trend is unexpected and possibly indicates that creatinine 
may act as a proxy for some other influence on usteki-
numab clearance, such as an unmeasured comorbidity. 
Zhu et al.25 additionally reported that diabetes, albumin 
level, and alkaline phosphatase level significantly affected 
clearance. Although the latter two measurements were 
unavailable in our cohort, we also found clearance to be 
around 30% higher in diabetic vs. nondiabetic patients. 
Possible factors accounting for this include decreased 
lymphatic function, increased glycation of ustekinumab, 
and differences in body composition.38,39 However, di-
abetes was not included in the final model as its effect 
was accounted for by waist circumference. Although we 
found higher bodyweight with a priori allometry to be 
the only covariate associated with increased volume of 
distribution, Zhu et al.25 additionally reported that diabe-
tes and ethnicity were significant covariates. Clearance 
was increased in the small number of patients in whom 
ADA were detected, reflecting the likely mechanism that 
complexes formed between ADA and therapeutic anti-
bodies trigger immune processes of internalization and 
lysosomal degradation.40
Regarding the PD model and considering the chronic na-
ture of psoriasis, we assumed a turnover model reflecting 
the dynamics of progression and remission of skin lesions 
over time. The turnover half-life of skin lesions was esti-
mated to be ~ 5 weeks, similar to the reported value used for 
the PD model derived from clinical trial data26 (34.7 days vs. 
22.1 days). Psoriasis turnover half-life (kout) was consistent 
for both (single and mixture) PD models (Table 3), and also for 
models that included all patients regardless of baseline PASI 
(Table S1). This implies that the turnover model captures 
the underlying disease trajectory, and is robust to changes 
in the drug effect model and baseline disease severity. In 
our study, EC50 was found to have a bimodal distribution, 
and unlike Zhou et al.’s study,26 a significant improvement 
in model fit was obtained with the mixture model. Based on 
the individual probabilities in the mixture model, EC50 es-
timates for the two subpopulations differed by ~  20-fold. 
Because most responsive patients were in the low EC50 
group and most nonresponsive patients were in the high 
EC50 group, this may imply that a Bayesian model taking 
into account patient covariates, initial PASI trajectory, and 
Figure 3 Simulated profiles using the mixture model of the probability of achieving PASI75 after 8 weekly, 12 weekly, and 16 weekly 
ustekinumab injections in the patient group on 45 mg (top), on 90 mg (middle), and simulating a 90 mg dose using parameters from the 
patient group on 45 mg (bottom) (Group 1: using parameters from mixture group 1, Group 2: using parameters from the mixture group 
2). PASI, Psoriasis Area Severity Index.
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ustekinumab concentration may help identify primary nonre-
sponders and guide dose adjustments in partial responders. 
Further automatic stratification into three subpopulations 
was unsuccessful, with no improvement in model fit or iden-
tification of three distinctive subgroups. This might be due 
to an insufficiently strong signal of PASI change over time, in 
particular within the nonresponder subgroup.
Strengths and limitations
This is the first PK/PD study of ustekinumab that draws on 
real-world clinical data, as opposed to clinical trial data. A 
key strength of our unique cohort is high external validity; 
> 50% of all UK patients with psoriasis taking biologics are 
registered on BADBIR, and 95% of UK dermatology cen-
ters prescribing biologics for psoriasis contribute data to 
BADBIR. It is, therefore, of substantial interest that key PK 
parameters are consistent between models derived from 
real-world vs. clinical trial data. While taking the same 
modelling approach as Zhu et al.25 and Zhou et al.,26 we 
maximized clinical relevance by including covariates al-
ready known to affect response to biologics across the 
BADBIR cohort. As reported elsewhere, we also confirm in 
our real-world cohort that ustekinumab has relatively low 
immunogenicity in the setting of clinical practice, with only 
3.3% of patients developing detectable ADA.23
Our study had some limitations. As with any real-world 
cohort, a key issue is missing data. For missing injection 
dates, we made the assumption of perfect patient compli-
ance without changes on doses and dosing regimen during 
treatment course. In the United Kingdom, ustekinumab in-
jections are almost always administered by nurses, and, 
therefore, nonadherence rates are low.41 For missing co-
variates, we replaced the missing values with medians or 
the most common categories. Unlike a clinical trial setting, 
there was no group of patients on placebo only, to give in-
sight into the untreated disease trajectory. There were also 
unbalanced and missing PK/PD observations from certain 
patients or at certain time points. However, these short-
comings did not seem to impact our population modelling 
results and interpretation, because parameter estimates 
were close to those reported from phase III clinical trials.25,26 
Of note, 60% of BADBIR centers recruit to the BSTOP study, 
whereby patients also consent to giving biological sam-
ples, so there remains inherent potential for bias in patient 
Figure 4 Individual predicted 4-week PASI change from baseline vs. 4-week ustekinumab trough concentration. (a) Predicted 4-week 
trough concentration by responder category; (b) predicted 4-week PASI decrease from baseline (%) by responder category; (c) 
predicted 4-week PASI decrease from baseline (%) vs. predicted 4-week trough concentration. In c, open circles represent patients 
who were full-responders at 6 months, triangles are partial-responders, and filled circles are nonresponders. Horizontal and vertical 
lines represent 4-week PASI cutoff of 25% decrease and 4-week trough concentration of 1.4 μg/mL, respectively. The numbers in each 
quadrant represent the percentage of 6-month full-responder, partial-responder, and nonresponders in each quadrant, respectively. 
PASI, Psoriasis Area Severity Index.
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selection. However, we have maximized inclusivity by not 
applying selection criteria for the current study cohort be-
yond needing ≥ 1 serum sample/PASI. Finally, our proposed 
clinical algorithm (Figure 4) is unsophisticated, and only ap-
plies to the 4-week time point.
Clinical implications
Using real-world clinical data, we present a PK/PD model 
for patients with psoriasis on ustekinumab, demonstrate 
potential utility in modifying ustekinumab dosing in cer-
tain patient subsets, and show that assessing trough 
concentration and PASI trajectory at week 4 is infor-
mative with respect to likely 6-month response. These 
findings require validation, but suggest that consider-
ation should be given both to the initial PASI response 
and ustekinumab trough concentration. To expand on 
this specifically, although finding a trough lower than 
1.4  μg/mL should generally prompt consideration of a 
dose increase, by simulating increased dosing frequen-
cies we have shown that the effect of this dose increase 
will likely also depend on initial PASI response. For such 
patients a good response (>  25% decrease) at week 4 
indicates a higher likelihood that partial response would 
have been achieved without a dose increase than does a 
poor 4-week response; our simulations show that a dose 
increase may “convert” such cases to full response. A 
poor early response with high 4-week trough levels would 
indicate a group with a low probability of response, and 
may indicate a primary nonresponder group where ther-
apy should be switched; certainly it would seem prudent 
to reassess PASI response in short order (e.g., another 
4  weeks). Currently, serum ustekinumab concentrations 
are only sporadically measured in routine clinical prac-
tice, and clinical response is not evaluated as early as 
4  weeks. Our recommendations point to a need for a 
change in practice, and should be evaluated in a prospec-
tive dose-intervention study.
In the future, similar models could be implemented into a 
Bayesian dashboard system, so that real-time predictions 
of response could be used to inform dosing and treatment 
switching decisions.42 Finally, integration of PK/PD models 
with genetic and other omic data may help identify disease 
endotypes, allowing further personalization of therapy for in-
dividual patients with psoriasis.
Supporting Information. Supplementary information accompa-
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